Apellis Pharmaceuticals Inc
APLS23.970USD
+1.020+4.44%
交易中 （美东）报价延迟15分钟
3.02B总市值
亏损市盈率 TTM
关于 Apellis Pharmaceuticals Inc 公司
Apellis Pharmaceuticals, Inc. 是一家商业阶段的生物制药公司。该公司专注于发现、开发和商业化新型治疗化合物，通过抑制补体系统来治疗高度未满足需求的疾病。SYFOVRE（pegcetacoplan 注射液）是该公司批准的治疗因年龄相关性黄斑变性 (GA) 而导致的地图样萎缩的药物。其 EMPAVELI（pegcetacoplan）用于治疗阵发性睡眠性血红蛋白尿 (PNH)。其 Aspaveli（pegcetacoplan）用于治疗使用 C5 抑制剂治疗至少三个月后仍贫血的 PNH 成人患者。系统性 pegcetacoplan 还已获准在日本、沙特阿拉伯、澳大利亚、英国和其他司法管辖区用于治疗 PNH。系统性 pegcetacoplan 在美国、沙特阿拉伯和澳大利亚以商品名 EMPAVELI 销售，在欧盟、日本和英国以商品名 Aspaveli 销售。
公司简介
公司代码APLS
公司名称Apellis Pharmaceuticals Inc
上市日期Nov 09, 2017
CEODr. Cedric Francois, M.D., Ph.D.
员工数量705
证券类型Ordinary Share
年结日Nov 09
公司地址100 Fifth Avenue
城市WALTHAM
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02451
电话16179775700
网址https://apellis.com/
公司代码APLS
上市日期Nov 09, 2017
CEODr. Cedric Francois, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
112.58K
-4.25%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%
Mr. Craig A. Wheeler
Mr. Craig A. Wheeler
Independent Director
Independent Director
16.48K
--
Ms. Keli Walbert
Ms. Keli Walbert
Independent Director
Independent Director
9.09K
--
Ms. Stephanie Monaghan O'Brien, J.D.
Ms. Stephanie Monaghan O'Brien, J.D.
Independent Director
Independent Director
955.00
-86.25%
Mr. Niel Carnahan
Mr. Niel Carnahan
Investor Contact
Investor Contact
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Cedric Francois, M.D., Ph.D.
Dr. Cedric Francois, M.D., Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
1.61M
-4.95%
Dr. Pascal Deschatelets, Ph.D.
Dr. Pascal Deschatelets, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
1.12M
+1.15%
Mr. Alec Machiels, J.D.
Mr. Alec Machiels, J.D.
Independent Director
Independent Director
1.01M
-0.59%
Mr. David Osborne Watson, J.D.
Mr. David Osborne Watson, J.D.
General Counsel, Secretary
General Counsel, Secretary
112.58K
-4.25%
Ms. Nur Nicholson
Ms. Nur Nicholson
Chief Technical Operations Officer
Chief Technical Operations Officer
71.83K
+59.79%
Dr. Caroline Baumal, M.D.
Dr. Caroline Baumal, M.D.
Chief Medical Officer
Chief Medical Officer
41.19K
+557.11%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
业务USD
名称
营收
占比
SYFOVRE
130.17M
78.04%
EMPAVELI
19.73M
11.83%
Licensing and other revenue
16.90M
10.13%
暂无数据
业务
地区
业务USD
名称
营收
占比
SYFOVRE
130.17M
78.04%
EMPAVELI
19.73M
11.83%
Licensing and other revenue
16.90M
10.13%
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Morningside Venture Investments, Ltd.
10.14%
Wellington Management Company, LLP
9.74%
Avoro Capital Advisors LLC
9.68%
EcoR1 Capital, LLC
9.42%
The Vanguard Group, Inc.
8.01%
Other
53.01%
持股股东
持股股东
占比
Morningside Venture Investments, Ltd.
10.14%
Wellington Management Company, LLP
9.74%
Avoro Capital Advisors LLC
9.68%
EcoR1 Capital, LLC
9.42%
The Vanguard Group, Inc.
8.01%
Other
53.01%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
47.44%
Investment Advisor
24.12%
Hedge Fund
15.28%
Research Firm
11.85%
Corporation
10.19%
Individual Investor
3.82%
Bank and Trust
1.65%
Pension Fund
1.30%
Private Equity
1.14%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
707
147.98M
117.74%
-16.68M
2025Q1
739
147.63M
117.48%
-17.38M
2024Q4
726
148.40M
118.39%
-6.44M
2024Q3
713
138.62M
113.64%
-12.05M
2024Q2
701
135.38M
111.32%
-9.63M
2024Q1
699
132.74M
109.77%
-12.51M
2023Q4
669
131.80M
110.59%
-13.78M
2023Q3
642
131.99M
111.79%
-7.62M
2023Q2
631
124.43M
106.07%
-15.68M
2023Q1
592
129.73M
111.79%
-2.40M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Morningside Venture Investments, Ltd.
12.81M
10.19%
--
--
Mar 31, 2025
Wellington Management Company, LLP
12.30M
9.79%
+502.40K
+4.26%
Mar 31, 2025
Avoro Capital Advisors LLC
12.22M
9.72%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
11.90M
9.46%
+4.96K
+0.04%
Mar 31, 2025
The Vanguard Group, Inc.
10.11M
8.05%
+84.33K
+0.84%
Mar 31, 2025
Morgan Stanley & Co. LLC
8.10M
6.44%
+40.85K
+0.51%
Mar 31, 2025
Deep Track Capital LP
7.00M
5.57%
+2.00M
+40.00%
May 09, 2025
BlackRock Institutional Trust Company, N.A.
5.43M
4.32%
-8.41K
-0.15%
Mar 31, 2025
AQR Capital Management, LLC
4.08M
3.24%
+2.22M
+119.64%
Mar 31, 2025
State Street Global Advisors (US)
3.94M
3.14%
-583.75K
-12.90%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Products ETF
1.73%
ALPS Medical Breakthroughs ETF
1.47%
Global X Guru Index ETF
1.21%
SPDR S&P Biotech ETF
0.63%
Direxion Daily S&P Biotech Bull 3X Shares
0.36%
Invesco Nasdaq Biotechnology ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.24%
iShares Biotechnology ETF
0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
First Trust Small Cap Growth AlphaDEX Fund
0.09%
查看更多
Virtus LifeSci Biotech Products ETF
占比1.73%
ALPS Medical Breakthroughs ETF
占比1.47%
Global X Guru Index ETF
占比1.21%
SPDR S&P Biotech ETF
占比0.63%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.36%
Invesco Nasdaq Biotechnology ETF
占比0.24%
ProShares Ultra Nasdaq Biotechnology
占比0.24%
iShares Biotechnology ETF
占比0.19%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.09%
First Trust Small Cap Growth AlphaDEX Fund
占比0.09%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
